Progenity (NASDAQ:PROG) and Aclarion (NASDAQ:ACON) Head to Head Analysis

Progenity (NASDAQ:PROG – Get Rating) and Aclarion (NASDAQ:ACON – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares Progenity and Aclarion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Progenity	-966.23%	N/A	-127.45%
Aclarion	-12,583.55%	N/A	-206.46%

Earnings and Valuation

This table compares Progenity and Aclarion’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progenity	$1.25 million	401.04	-$247.41 million	($2.81)	-0.97
Aclarion	$60,000.00	85.15	-$7.61 million	N/A	N/A

Aclarion has lower revenue, but higher earnings than Progenity.

Institutional & Insider Ownership

62.8% of Progenity shares are owned by institutional investors. Comparatively, 2.0% of Aclarion shares are owned by institutional investors. 79.3% of Progenity shares are owned by company insiders. Comparatively, 22.1% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Progenity and Aclarion, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progenity	0	0	0	0	N/A
Aclarion	0	0	1	0	3.00

Aclarion has a consensus target price of $3.00, indicating a potential upside of 361.54%. Given Aclarion’s higher possible upside, analysts plainly believe Aclarion is more favorable than Progenity.

Summary

Progenity beats Aclarion on 6 of the 9 factors compared between the two stocks.

About Progenity

(Get Rating)

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

About Aclarion

(Get Rating)

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.